Craig-Hallum bullish on SAB Biotherapeutics, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of SAB Biotherapeutics with a Buy rating and $11 price target The firm believes the company’s unique ability to produce human polyclonal antibodies offers profound opportunities for developing novel therapies, led by SAB-142. SAB-142 has a clear value proposition that builds on rabbit ATG’s clinically validated mechanism of action in delaying the onset of T1D. As a human ATG, SAB-142 overcomes the safety limitations of rabbit ATG, making it a re-dosable disease-modifying therapy that enables long-term T1D disease prevention, Craig-Hallum says. The firm sees opportunity for share appreciation as SAB-142 proceeds through development, where clinical data gives it confidence that SAB-142 can be the best-in-class therapy for long-term T1D prevention.